The fact
The drug targets patients with severe adiposity across Europe.
Its launch reignites debates over access to care for chronic diseases.
Click the link to read an article on the topic:
The drug targets patients with severe adiposity across Europe.
Its launch reignites debates over access to care for chronic diseases.